Significance of changes in tumor markers in patients treated with durvalumab plus tremelimumab combination therapy as a surrogate marker for tumor response to unresectable hepatocellular carcinoma.
Shinsuke UchikawaTomokazu KawaokaSerami MurakamiRyoichi MiuraYuki ShiraneYusuke JohiraMasanari KosakaYasutoshi FujiiHatsue FujinoAtsushi OnoEisuke MurakamiDaiki MikiC Nelson HayesMasataka TsugeShiro OkaPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2024)
The change in tumor markers is a more useful predicter of tumor response to Dur + Tre than imaging evaluation alone.